BRENDAN GREENAWAY: Open Payments
NPI 1841632072 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 50 payments from 15 companies in 2025. Trend: 2023 $483 · 2024 $1,261 · 2025 $1,329
Food & beverage: $1,329
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $276 |
| Axsome Therapeutics, Inc. | 7 | $254 |
| ABBVIE INC. | 10 | $221 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $155 |
| Noven Therapeutics, LLC | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Bausch Health US, LLC | 2 | $43 |
| Lundbeck LLC | 1 | $32 |
Products named: INGREZZA, Auvelity, VRAYLAR, CAPLYTA, Xelstrym, REXULTI, TRINTELLIX, Jornay PM.
Industry payments across CA — which companies pay providers there.
